Nanofàrmacs

SPHERICAL NUCLEIC ACIDS WITH TAILORED AND ACTIVE PROTEIN CORONAE

Resumen de: US2025270250A1

The disclosure is generally related to spherical nucleic acids (SNAs) comprising a protein corona, wherein the SNA comprises (i) a nanoparticle core and (ii) one or more oligonucleotides attached to the surface of the nanoparticle core, wherein the protein corona comprises a plurality of proteins. The disclosure also provides methods of using the same. The disclosure further provides methods of improving stability and/or extending blood circulation half-life of a spherical nucleic acid (SNA), the SNA comprising a nanoparticle core and one or more oligonucleotides attached to the surface of the nanoparticle core, the method comprising adsorbing a plurality of proteins on the surface of the SNA.

GEL LOADED WITH ALPHA-EMITTER RADIONUCLIDES

Resumen de: AU2024208905A1

A mixture for treating a tumor, which includes an agent which turns into a hydrogel by addition of calcium ions, a vehicle carrying the agent in a manner allowing injection of the mixture into a tumor; and radium radionuclides bonded to the agent in a concentration sufficient to treat the tumor by radiotherapy.

METHODS OF MAKING AND ISOLATING CIRCULAR RNAS AND CIRCULAR RNA COMPOSITIONS

Resumen de: AU2024211148A1

Provided herein is a method of making circular RNA, a method of isolating circular RNA and compositions comprising circular RNA.

NANOPARTICLES FOR DELIVERY OF NUCLEIC ACID CARGOS

Resumen de: AU2024213893A1

Nanoparticles suitable for delivery of a linear DNA molecule are provided. Nanoparticles suitable for delivery of mRNA or DNA are provided. Further provided are uses of the nanoparticles including the use of the nanoparticles for treating disease and the use of the nanoparticles in vaccines.

HYDROPHOBIC SYNTHETIC MELANIN NANOPARTICLES

Resumen de: AU2023380329A1

Aspects disclosed herein include a material and formulations having the material, the material comprising functionalized artificial melanin nanoparticles, wherein: each functionalized artificial melanin nanoparticle comprises a surface functionalized with a modifier agent via a linker group; wherein the modifier agent comprises the linker group and a functional group attached to the linker group; and wherein the linker group is an amine group. Aspects also include a method of healing skin damage using the disclosed formulations.

LYMPHATIC ENDOTHELIAL CELL-SPECIFIC LIPID NANOPARTICLE AND USES THEREOF

Resumen de: WO2024086810A1

The present disclosure relates to lymphatic endothelial cell (LEC)-specific lipid nanoparticle comprising a sterol, an ionizable lipid, a PEGylated lipid, and a phospholipid. Also disclosed herein are compositions comprising the LEC-specific lipid nanoparticle and a therapeutic agent. The present disclosure further relates to methods of delivering an agent to a lymphatic system in a subject, comprising administering to the subject an effective amount of the composition of the LEC-specific lipid nanoparticle and therapeutic agent.

A GRAPHENE-ANTICANCER PEPTIDE COMPLEX WITH NANOHOLE

Resumen de: WO2024085837A1

The invention relates to the biocompatible complex formed by binding a pyrene- methanol-bonded therapeutic peptide (Cycas Revoluta anticancer peptide 1, Cr-ACP1) to the quadrilateral graphene nanohole surface with a defective structure, and the synthesis method of this complex. With the therapeutic peptide attached to the biocompatible complex, treatment is provided to healthy tissues with minimal side effects, and the transport of said complex to the cancer cell occurs in a controlled manner.

METHODS OF ANALYZING LIPID NANOPARTICLES IN PHYSIOLOGICAL FLUIDS

Resumen de: CN120035760A

Methods and systems for analyzing lipid nanoparticles using size exclusion chromatography in combination with multi-angle light scattering are disclosed.

GENERATION OF SECRETOME-CONTAINING COMPOSITIONS, AND METHODS OF USING AND ANALYZING THE SAME

Resumen de: CN120225659A

The present disclosure provides methods for producing and/or purifying secretory groups, extracellular vesicles, and fractions thereof from progenitor cells; also provided are compositions containing such secretion-producing groups, extracellular vesicles, and fractions thereof. The present disclosure also provides methods of analyzing the activity, function, and potency of these secretory groups, extracellular vesicles, and fractions thereof. The present disclosure also relates to therapeutic uses of secretograms, extracellular vesicles and fractions thereof. The present disclosure also relates to scalable culture regimens that comply with good production specifications (GMP) for issuing clinically available secretory groups.

LIPID COMPOSITION AND METHOD OF DELIVERING THERAPEUTIC AGENT

Resumen de: US2025242049A1

It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem/progenitor cells or mesenchymal stem cells.

INHIBITORS FOR FRA-1 AND FRA-2 FOR USE IN THE TREATMENT OF ORGAN OR TISSUE FIBROSIS

Resumen de: WO2024084007A1

The present invention relates to inhibitors, pharmaceutical compositions and methods for inhibiting the expression of Fos-related antigen-1 (Fra-1) or Fos-related antigen-2 (Fra-2) in fibrogenic tissue cells for use in the treatment or prevention of organ or tissue fibrosis. The inhibitor of the present invention is characterized in that it interferes with Fra-1 or Fra-2 expression, resulting in a reduction in the amount of Fra-1 or Fra-2 in said fibrogenic cells to levels found in non-fibrotic healthy cells or tissues.

ANTIVIRAL NUCLEIC ACIDS AND COMPOSITIONS

Resumen de: CN120092089A

The present invention relates generally to compositions and methods for inhibiting coronavirus replication and treating diseases caused by coronavirus infection. More specifically, the present invention provides nucleic acids capable of inhibiting replication of coronavirus (e.g., SARS-CoV-2) and their use in treating viral infected patients.

METHOD FOR FUSING LIPID NANOPARTICLES

Resumen de: EP4606370A1

According to one embodiment of the present disclosure, a method for fusing lipid nanoparticles is provided. In some embodiments, the method is a method including: causing a fibrous structure to capture a first lipid nanoparticle; causing the fibrous structure to capture a second lipid nanoparticle; and causing the fibrous structure to contract.

METAL-POLYPHENOL COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF

Resumen de: EP4606388A1

The disclosure relates to the technical field of biological medicines, and particularly provides a metal-chelated polyphenol complex nanoparticle, a drug-lipid particle, preparation methods for the same, and the uses thereof. The present disclosure provides a metal-chelated polyphenol complex as a carrier for drugs for stability, delivery and the like, so that it interacts with other carriers to form a metal-chelated polyphenol complex nanoparticle for effective administration of negatively charged drug. High-efficiency systemic drug delivery can be achieved, while toxicity is significantly reduced compared to LNP containing cationic or ionizable lipids, enabling safe and effective treatment of diseases or disorders.

LIPID NANOPARTICLES FOR NUCLEIC ACID DELIVERY

Resumen de: WO2024125823A1

The invention relates to new Lipid nanoparticles (LNPs) which can be used for nucleic acid delivery, wherein said LNPs comprise a nucleic acid and a nonionic or cationic cyclodextrin compound. The invention also relates to a process for making the same, and to the use thereof in the pharmaceutical field.

METHODS AND USES ASSOCIATED WITH LIQUID COMPOSITIONS

Resumen de: WO2024084089A1

Methods, systems, and uses for providing a lipid nanoparticle composition with advantageous nanoparticle properties are provided.

MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARBECOVIRUSES

Resumen de: WO2024082067A1

Described herein is a fusion polypeptide comprising a sarbecovirus binding moiety linked to a nanocage monomer or subunit thereof, wherein the sarbecovirus binding moiety is capable of binding to SARS-CoV-2 and at least one sarbecovirus other than SARS-CoV-2. Also described are methods for treating and/or preventing sarbecovirus infection and/or a sarbecovirus-associated condition.

两性离子脂质及其组合物和应用

Resumen de: CN120535438A

本发明提供了一种两性离子脂质及其组合物和应用，属于生物医药技术领域。该两性离子脂质具有如下式（I）所示结构：#imgabs0#，（I）；R1和R2各自独立地选自单键、或者取代或未取代的C1~C20饱和或不饱和烷基；R1的n1个或R2的n2个亚甲基各自独立地被‑O‑、‑C(O)‑、‑C(O)O‑或‑C(O)NH‑所置换；且取代或未取代的C1~C20饱和或不饱和烷基上有取代基时，取代基选自羟基、巯基、C1~C20烷基中的一种或多种的组合。本发明两性离子脂质可以提升脂质纳米颗递送系统的转染率，提高核酸递送效率。

一种基于金属有机框架的卡巴拉汀纳米粒及其制备方法

Resumen de: CN120531687A

本发明公开了一种基于金属有机框架的卡巴拉汀纳米粒及其制备方法，属于纳米药物技术领域。本发明金属有机框架为ZIF‑8，将卡巴拉汀封装负载于ZIF‑8孔隙内形成核‑壳结构，同时在ZIF‑8表面负载乳铁蛋白LF，形成LF‑Riv@ZIF‑8纳米粒。本发明利用ZIF‑8材料的高孔隙结构对卡巴拉汀进行封装负载，制备一种卡巴拉汀抗阿尔兹海默纳米粒，改善由于卡巴拉汀低水溶性、生物利用度低，胃肠道副反应较多及光热敏感性的特点导致的应用局限性。

预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用

Resumen de: CN120531703A

本发明提供预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用，属于生物医药技术领域。本发明的预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用，包括将预制载体与核酸在溶剂中混合，得到基于预制载体的组合物的步骤；所述预制载体组成包括：可电离脂质、磷脂、胆固醇以及聚乙二醇缀合脂质。本发明所述预制载体，可用于细胞及基因治疗的载体工具。

一种靶向肺炎的仿生纳米系统及其制备方法和应用

Resumen de: CN120531700A

本发明公开了一种靶向肺炎的仿生纳米系统及其制备方法和应用。所述靶向肺炎的仿生纳米系统包括包载抗菌药物的纳米颗粒，和包覆于所述纳米颗粒表面的NK细胞膜。本发明首次基于NK细胞膜实现仿生纳米系统靶向到细菌的定植部位，躲避巨噬细胞的吞噬以及穿透细菌形成的黏液层，开发针对肺炎抗菌药物的递送系统，为抗菌药物的递送提供了新思路、新方法。

一种仿生纳米调节剂的制备方法及应用

Resumen de: CN120531704A

本发明涉及生物技术领域，特别涉及一种仿生纳米调节剂的制备方法及应用。本发明提供了仿生纳米调节剂，所述纳米调节剂包括治疗药物；所述治疗药物包括：Ce6和SB525334。将细菌外膜囊泡与包封Ce6和SB525334药物的PLGA通过挤压得到仿生纳米调节剂。在光动力治疗下，仿生纳米调节剂可以被中性粒细胞识别、摄取并递送至肿瘤组织。仿生纳米调节剂可以调控中性粒细胞向抗肿瘤N1型极化，并促进中性粒细胞释放中性粒细胞弹性蛋白酶，特异性杀伤肿瘤细胞，逆转肿瘤免疫抑制微环境。仿生纳米调节剂在光动力‑免疫疗法的联合治疗下，显著抑制肿瘤生长，增强了机体抗肿瘤免疫应答。

一种用于治疗干眼症的白藜芦醇纳米制剂及其制备方法

Resumen de: CN120531701A

本发明属于干眼症治疗领域，涉及一种用于治疗干眼症的白藜芦醇纳米制剂及其制备方法。白藜芦醇纳米制剂包括白藜芦醇，以及丝胶蛋白与甘草酸通过互穿作用形成的复合载体，所述复合载体包封所述白藜芦醇。本发明通过采用丝胶蛋白与甘草酸互穿形成的复合载体对白藜芦醇进行包封，有效地解决了传统白藜芦醇在治疗干眼症过程中因生物利用度低而导致的疗效不佳问题。该复合载体能够包封白藜芦醇，形成稳定的纳米丝状结构，该纳米丝状结构具有小于10nm的水动力直径，极大地提升了白藜芦醇的口服生物利用度以及在眼部组织的分布能力，进而显著提升白藜芦醇口服治疗干眼的药效。

预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用

Resumen de: CN120531702A

本发明提供预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用，属于生物医药技术领域。本发明的预制载体在制备用于免疫细胞和干细胞的体外基因递送的产品中的应用，包括将预制载体与核酸在溶剂中混合，得到基于预制载体的组合物的步骤；所述预制载体组成包括：可电离脂质、磷脂、胆固醇以及聚乙二醇缀合脂质。本发明所述预制载体，可用于细胞及基因治疗的载体工具。

BODIPY衍生物和纳米制剂、相应的制备方法与用途

Resumen de: CN120535540A

本发明公开了一种BODIPY衍生物和纳米制剂、相应的制备方法与用途，所述BODIPY衍生物以氟硼二吡咯为母核，通过调整取代基、扩展共轭体系制得。本发明的BODIPY衍生物和纳米制剂，其发射波长能够延伸至NIR‑II区，可以用来制备抑制肿瘤细胞生长的药物或近红外二区荧光成像剂。

一种含纳米粒的双层口腔膜及其制备方法和应用

Resumen de: CN120531710A

本发明公开了一种含纳米粒的双层口腔膜及其制备方法和应用，本发明采用双层浇铸法，将普鲁兰多糖溶于水后加入甘油、柠檬酸、白藜芦醇‑牛血清白蛋白纳米粒(Res‑BSA)，搅拌除去气泡后倾倒背衬层上，干燥即可，其中背衬层为罗望子多糖(TSP)溶于水后加入甘油干燥制得，白藜芦醇‑牛血清白蛋白纳米粒包括以牛血清白蛋白(BSA)、白藜芦醇(Res)、葡萄糖为原料制得。发明制备的双层膜可强化活性物单向释放至口腔黏膜，提高活性物的递送效率。本发明在双层膜的活性物层中添加活性物纳米粒，该纳米粒具有黏液惰性，能高效穿透黏液层。

基于纳米颗粒介导的靶向药物递送系统肝癌介入治疗方法

Resumen de: CN120544783A

本发明公开了一种基于纳米颗粒介导的靶向药物递送系统肝癌介入治疗方法，S1.提供一组纳米颗粒作为药物载体，并赋予纳米颗粒靶向肝癌细胞的特性；S2.根据肝癌患者的生物特征，通过成像技术获取肝癌区域目标定位信息；S3.基于肝癌区域目标定位信息，使用莱维飞行优化算法对纳米颗粒的分布进行优化；S4.根据优化后的分布路径，将药物载体与药物结合，并按照优化路径输送至肝癌区域；S5.在肝癌区域释放药物，并使药物靶向肝癌细胞；S6.根据药物释放情况，通过实时监控调整药物释放策略，优化治疗效果。本发明不仅提升了药物递送的精准度，还显著提高了治疗效果，为肝癌治疗提供了更有效的技术手段。

脂质化合物、脂质纳米颗粒和药物组合物

Resumen de: CN120535478A

本申请提供了脂质化合物，例如式(I)的化合物。还提供了脂质纳米颗粒和药物组合物，其各自包含脂质化合物，例如下式的化合物。#imgabs0#

一种增强癌症免疫治疗的工程化细胞囊泡纳米疫苗的制备方法及其应用

Resumen de: CN120514832A

本发明提供了一种增强癌症免疫治疗的工程化细胞囊泡纳米疫苗的制备方法及其应用，属于生物医药技术领域，所述制备方法包括：机械挤压经热休克处理的肿瘤细胞，获得TEV；将氯化钠、盐酸和四甲氧基硅烷溶于水，获得硅酸溶液，后加入所述TEV，孵育得到Si@TEV；将聚乙烯亚胺溶于有机溶剂，后加入氟化试剂3‑全氟己基‑1，2‑环氧丙烷，经搅拌反应、透析和冻干，获得F‑PEI；将所述F‑PEI溶于PBS，后加入所述Si@TEV,经搅拌反应、洗涤和离心，获得纳米疫苗F‑PEI/Si@TEV。该方法制备的工程化细胞囊泡纳米疫苗稳定性好，能够有效提高机体抗肿瘤免疫应答，强效杀伤肿瘤细胞，可应用于不同类型肿瘤防治。

新薬物複合体

Resumen de: JP2025123209A

【課題】薬物の送達技術に利用可能な新規コポリマーを提供する。【解決手段】次の式（Ａ）、（Ｂ）及び（Ｃ）で示される構造単位からなるコポリマーＸに標的認識分子が結合した薬物複合体。TIFF2025123209000105.tif59170（式中、Ｒ１、Ｒ２及びＲ３はＨ又はＣ１－３アルキル、Ｒ４はＣ１－３アルキル、Ｒ５はＨ、Ｃ１－１８アルキル、３～８員シクロアルキル、アダマンチル、Ｃ６－１８アリール又は５～１０員へテロアリール、Ｘ１、Ｘ２及びＸ３はＯ、Ｓ又はＮ－Ｒ７、Ｒ６はＨ、脱離基、リンカー、Ｒ７はＨ又はＣ１－３アルキル基、ｍは１～１００、ｎは０～３）【選択図】なし

脂质化合物、脂质纳米颗粒和药物组合物

Resumen de: CN120035576A

Provided herein are lipid compounds, such as compounds of Formula (I). Also provided are lipid nanoparticles and pharmaceutical compositions, each comprising a lipid compound, such as a compound of Formula (I). # imgabs0 #

一种负载siRNA和小分子药物的纳米药物系统及其制备方法和应用

Resumen de: CN120514721A

本发明属于纳米药物系统技术领域，具体涉及一种负载siRNA和小分子药物的纳米药物系统及其制备方法和应用，包括设计合成含siRNA分子序列的环状DNA模板，并通过滚环转录(Rolling Cycle Transcription，RCT)反应，合成含预设计siRNA分子的长串联重复RNA链，并自组装形成的核酸颗粒RNs。将小分子抑制剂CB839嵌入RNs中后，经表面修饰，生物相容性脂质膜包覆，靶向肽修饰等步骤得到本发明同时负载siRNA和小分子药物的纳米药物系统LNPs@RNCPsGPC3，本发明可以大幅提高siRNA及CB839递送效率和生物安全及相容性，特异性靶向肝癌细胞，阻断肿瘤细胞内依赖性氨基酸代谢通路并抑制其主动恢复微环境平衡的GCN2‑eIF2α‑ATF4通路轴，来杀死肿瘤细胞。

一种靶向给药系统MnO2@HSA-DOX及其在肿瘤成像和治疗中的应用

Resumen de: CN120514682A

本发明公开了一种靶向给药系统MnO2@HSA‑DOX及其在肿瘤成像和治疗中的应用，所述MnO2@HSA‑DOX具有肿瘤微环境酸响应的特点，可实现在肿瘤微环境中快速降解和释放，释放Mn2+和DOX，实现肿瘤区域的特异成像的同时释放化疗药物DOX，进而实现诊疗一体化，具有良好的生物安全性，这一创新性纳米材料整合了治疗与成像能力，为癌症的精准诊断与治疗提供了全新的综合平台，临床应用前景广阔。

中草药与海洋提取物联合用于抗菌抗炎的药物组合物

Resumen de: CN120514729A

本发明涉及药学领域，公开了中草药与海洋提取物联合用于抗菌抗炎的药物组合物，按重量份计包括：黄芩苷提取物5～10份；穿心莲内酯提取物3～7份；硫酸化褐藻多糖2～5份；海绵素提取物0.2～1份；其中：黄芩苷提取物来源于黄芩根部，经乙醇‑水混合溶剂提取得到；穿心莲内酯提取物来源于穿心莲全草，经乙醇‑水混合溶剂提取得到；硫酸化褐藻多糖来源于褐藻，经酶解和醇沉方法制备；海绵素提取物来源于海绵，经有机溶剂萃取及分离纯化得到。通过采用中草药活性成分与海洋提取物协同复合的技术方案，达到了在细菌性阴道炎、念珠菌性阴道炎伴生生物膜感染及宫颈炎治疗中，破坏生物膜屏障、清除顽固感染灶的技术效果。

一种碳核阳离子脂质

Resumen de: CN118265692A

The invention provides a cationic lipid and a preparation method thereof, a lipid composition containing the cationic lipid, an LNP-pharmaceutical composition containing the lipid composition and a preparation of the LNP-pharmaceutical composition, particularly the LNP-pharmaceutical composition containing the cationic lipid and the preparation of the LNP-pharmaceutical composition, which have the characteristics of high delivery efficiency and high biocompatibility. Therefore, the treatment effect and the prevention effect of the medicine are improved. The structure of the cationic lipid is shown as a general formula (1), and the definition of each symbol in the formula is described in the specification. # imgabs0 #

一种用于治疗肝损伤的纳米配位聚合物及其制备方法

Resumen de: CN120518875A

本发明公开了一种用于治疗脓毒症诱导的肝损伤的纳米配位聚合物的制备方法，包括以下步骤：1、甘草次酸和金属离子通过配位作用形成甘草次酸/金属离子配位纳米粒；2、在碱性条件下让多巴胺单体自聚于所述甘草次酸/金属离子配位纳米粒表面，形成以甘草次酸/金属离子配位纳米粒为核，聚多巴胺为壳的核壳结构纳米粒；3、将针对HMGB1蛋白设计的基因沉默工具连接于所述核壳结构纳米粒表面，得到用于治疗脓毒症诱导的肝损伤的纳米配位聚合物。本发明还公开了上述制备方法制备得到的用于治疗脓毒症诱导的肝损伤的纳米配位聚合物。本发明实现了治疗脓毒症诱导的肝损伤的药物防治和基因沉默治疗的联合应用。

一种纳米载体靶向递送anti-miR410反义寡核苷酸的制剂及其制备方法和应用

Resumen de: CN120514681A

本发明提供了一种纳米载体靶向递送anti‑miR410反义寡核苷酸的制剂及其制备方法和应用，属于生物医用材料技术领域。本发明首先提供了一种叶酸受体靶向纳米颗粒，然后将叶酸受体靶向纳米颗粒与反义寡核苷酸混合孵育得到靶向递送反义寡核苷酸的复合物。本发明靶向递送反义寡核苷酸的复合物在发挥anti‑miR410特异性增强肿瘤细胞放疗敏感性的同时又有抑制肿瘤细胞增殖和侵袭迁移的作用，更有利于提高肿瘤患者的完全缓解率、延长生存期、改善生活质量。本发明为开发肺癌放疗增敏的新策略提供了理论依据和实验基础，具有重要的科学意义和临床价值。

一种负载姜黄素与抗菌肽的纳米颗粒及其制备方法、应用

Resumen de: CN120514850A

本发明属于生物医药与纳米技术领域，具体涉及一种负载姜黄素与抗菌肽的纳米颗粒及其制备方法、应用。该负载姜黄素与抗菌肽的纳米颗粒是以PEI‑PLGA和姜黄素为原料，制备得到PEI‑PLGA‑Cur纳米颗粒；以PEI‑PLGA‑Cur纳米颗粒和抗菌肽为原料，制备得到所述负载姜黄素与抗菌肽的纳米颗粒。本发明提供的负载姜黄素与抗菌肽的纳米颗粒具有光动力治疗效果，纳米颗粒中姜黄素的载药量较高、抗菌肽的负载率较大，辅料安全，制作工艺简单，纳米颗粒粒径较小并且均一，血液相容性好，可以针对耐药菌的感染进行治疗，具有成为新型纳米抗菌药物的潜力和临床应用前景。

一种人工肽及其在核酸递送中的应用

Resumen de: CN120518709A

本发明涉及一种人工肽及其在核酸递送中的应用，所述人工肽由至少含有一个半胱氨酸的单链多肽和季戊四醇四丙烯酸酯经加成反应得到，其结构式为：#imgabs0#其中，R1为单链多肽序列，S为所述单链多肽序列中的半胱氨酸上的硫元素。由该人工肽与核酸药物分子形成的脂质纳米颗粒具有肝外器官靶向性、体内递送效果好且安全性好。

一种基于超声乳化-化学交联制备靶向递送大麻二酚纳米粒的方法及其应用

Resumen de: CN120514683A

本发明属于医药技术领域，具体涉及一种基于超声乳化‑化学交联制备靶向递送大麻二酚纳米粒的方法及其应用。本发明首先以高取代度羧甲基壳聚糖为阳离子骨架，通过pH敏感型腙键连接叶酸受体靶向配体，并构建二硫键桥联的3,3′‑二硫代二丙酸(DTPA)螯合冠层，形成“核‑壳‑冠”异质结构；然后采用超声乳化‑溶剂梯度扩散法包载大麻二酚，获得粒径均一的靶向递送大麻二酚纳米粒。该纳米粒能够有效实现大麻二酚的精准控释，不仅具有较高的靶向内吞效率与优异的药物缓释性能，还能有效抑制非靶组织的药物蓄积，从而显著提升抗肿瘤疗效与安全性，在TNBC的靶向治疗、精准医学及新型纳米药物开发领域具有重要应用价值。

一种多重包裹神经酰胺纳米颗粒及其制备方法和应用

Resumen de: CN120514620A

本发明提供了一种多重包裹神经酰胺纳米颗粒及其制备方法和应用，涉及医药和化妆品技术领域。本发明提供的多重包裹神经酰胺纳米颗粒，包括神经酰胺脂质体和包裹所述神经酰胺脂质体的聚合物层，所述神经酰胺脂质体包括神经酰胺和包裹所述神经酰胺的脂质体，所述脂质体为磷脂和胆固醇形成的脂质双分子层。本发明对神经酰胺进行多重包裹，脂质体的包裹能够保护神经酰胺免受外界环境破坏，一定程度提高神经酰胺的皮肤渗透性；聚合物包裹提供额外的保护层，增强稳定性。本发明提供的多重包裹神经酰胺通过结合脂质体、纳米颗粒和微胶囊技术，显著提高了神经酰胺的稳定性、渗透性和功效，使得神经酰胺能够渗透到真皮层或者更深处发挥作用。

一种蛋白-多糖递送系统包封姜黄素及其制备方法与在神经保护中的应用

Resumen de: CN120514119A

本发明属于食品加工技术领域，具体涉及一种负载姜黄素的蛋白‑多糖纳米粒子递送系统及其制备方法和在神经保护中的应用。制备方法为：取酪蛋白酸钠与葡聚糖、果胶两种多糖中的一种混合溶解，0‑4℃下水化12‑24h，进行超声和微波处理，得到预处理溶液；调节pH，加热预处理溶液，得到共价接枝颗粒；将步骤二得到的蛋白‑多糖共价接枝颗粒通过pH shift方法包封姜黄素，得到蛋白‑多糖‑姜黄素纳米颗粒。本发明提供一种通过超声和微波辅助酪蛋白酸钠-多糖进行美拉德反应的方法，优化反应参数，构建一种高效、稳定的姜黄素递送系统制备方法及在神经保护上的应用。

マイクロカプセル及びそのカプセル化プロセス

Resumen de: MX2025000955A

The invention relates to a polymeric shell and lipophilic active-core material based microcapsule with improved thermal stability.

脂質ナノ粒子の組成物

Resumen de: CN119654141A

Provided herein are lipid nanoparticle compositions comprising a cationic lipid, a steroid, a polymer-bound lipid, and no more than 0.5 mole percent of a phospholipid, which can be used to deliver a therapeutic payload (e.g., mRNA, siRNA, DNA) for therapeutic or prophylactic purposes.

ターゲティングされた遺伝子抑制によるＢ型肝炎ウイルスの調節のための組成物、システム、および方法

Resumen de: MX2025001508A

Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas/guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and/or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

標的送達のためのカンナビノイドデンドリマー組成物

Resumen de: CN119789874A

The present invention provides dendrimer formulations comprising one or more cannabinoids and/or cannabinoid derivatives and methods of use thereof for targeted delivery, particularly to neurons and activated microglial cells, or other cells on which the CB1 or CB2 receptor is expressed. The cannabinoid-dendrimer conjugate can be administered to patients in need of treatment of various diseases, the various conditions include central and peripheral nerve diseases, chronic pain, neuropathic pain, neurodegeneration (senescence, dementia, Alzheimer's disease), traumatic brain injury, epileptic seizure, Huntington's disease and multiple sclerosis, epilepsy, inflammatory diseases, and pain.

ＦＳＨＲの新規なモジュレータおよびその使用

Resumen de: MX2025002260A

Disclosed herein are novel FSH modulator compounds, formulations thereof, and methods of treating diseases by administration of one or more novel FSH modulator compounds.

ホウ素化ナノスケール基材及びその使用

Resumen de: WO2024044621A1

Various aspects described herein relate to a functionalized nanoscale substrate. The functionalized nanoscale substrate includes a functionalized surface of the substrate that includes a boronated portion.

一种含脂溶性功能因子的纳米复合物及其制备方法与应用

Resumen de: CN120514684A

本发明涉及纳米复合材料技术领域，具体为一种含脂溶性功能因子的纳米复合物及其制备方法与应用，本发明通过对脱支淀粉进行醚化改性，增加淀粉的亲水性并赋予淀粉负电荷，再与醇溶蛋白（Zein）基于静电、疏水、氢键相互作用对姜黄素、虾青素等脂溶性功能因子进行复合包埋，形成均一规则的纳米复合物，该复合物的pH、离子强度和热稳定性较高，颗粒粒径小，对姜黄素、虾青素等脂溶性功能因子的包埋率和装载量较高。此外，本发明采用连续制备工艺，避免了中间冷冻干燥再复溶的步骤，极大地简化了工艺流程。

LANTHANIDE-DOPED UPCONVERTING NANOPARTICLES

Resumen de: WO2025174811A1

Disclosed herein are lanthanide-doped upconverting nanoparticles and methods of making the same. Also disclosed are methods of imaging target proteins and methods of performing single particle tracking comprising the upconverting nanoparticles of this disclosure.

ヒストンメチルトランスフェラーゼ核局在化の新規阻害剤

Resumen de: MX2025000539A

The present invention relates to novel therapeutic compositions and methods for treating cancer. In particular, the use of proteinaceous inhibitors, including novel bicyclic peptide inhibitors, for use in treating cancer.

NANODRUG PRODUCT WITH CONTROLLED RELEASE OF HOCL AT TUMOR SITE FOR LUNG CANCER TREATMENT

Resumen de: WO2025172762A1

This invention introduces a method of development for a nanodrug that releases HOCl at tumor sites for treating lung cancer. The process involves creating alginate chitosan nanoparticles, measuring folate conjugation to chitosan, studying the properties of the nanoparticles, assessing HOCl release and cytotoxicity, and evaluating the impact on cancer cells by analyzing protein expression. Additionally, the penetration and effects of the nanoparticles are studied in a mouse model of lung cancer to understand their behavior in vivo. Overall, this patent aims to develop a targeted and effective treatment for lung cancer with minimal side effects on healthy tissues.

NANOPARTICLES

Resumen de: WO2025171440A1

Lipid-based nanoparticles containing lipids, phenolic compounds, and, optionally, metal ions are provided. In certain forms, the nanoparticles adopt non-lamellar, lyotropic, liquid crystalline structures. Bioactive lipid-based nanoparticles containing one or more active agents are also provided as are methods of treating diseases or conditions with said bioactive lipid-based nanoparticles and formulations thereof.

METHOD OF PACKAGING A PROTEIN, AN RNA OR A PROTEIN-RNA COMPLEX INTO A PARTICLE

Resumen de: WO2025172945A1

The invention relates to the field of medicine, and more particularly to bioengineering, genetic engineering, gene editing, molecular medicine, nanotechnology, biotechnology, nanoengineering and protein engineering. The invention can be used for packaging a Cas protein and a guide RNA, separately or together in the form of ribonucleoprotein complexes, and for packaging a Cas protein and a guide RNA of any class, type, form, origin and modification.

PARTICLES AND METHODS FOR MODIFYING B CELLS

Resumen de: WO2025175107A1

Disclosed herein are compositions and methods for modifying B cells. Particles such as hydrophobic microparticles or nanoparticles are described for use in delivering agents to B cells, generating regulatory B cells and inducing IL-10 production by B cells. Particles, or B cells bound to the same, are also provided for use in methods for treating an inflammatory or autoimmune disease or condition, inducing immune tolerance, and sustained delivery of an agent to a subject.

COMPOSITIONS AND METHODS FOR DELIVERY OF RNA

Resumen de: US2025263678A1

The disclosure relates to compositions and methods for the treatment of fibrotic diseases and disorders and/or liver diseases and disorders, with one or more synthetic messenger ribonucleic acids (mRNAs) encoding telomerase reverse transcriptase (TERT).

AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR

Resumen de: US2025263675A1

Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a poly peptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

DISPERSIONS FOR ADDITIVE MANUFACTURING COMPRISING DISCRETE CARBON NANOTUBES

Resumen de: US2025262894A1

The present invention is directed to additive manufacturing compositions and methods for producing additive manufacturing composite blends with oxidized discrete carbon nanotubes with dispersion agents bonded to at least one sidewall of the oxidized discrete carbon nanotubes. Such compositions are especially useful when radiation cured, sintered or melt fused.

POLYNUCLEOTIDES ENCODING URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1 FOR THE TREATMENT OF CRIGLER-NAJJAR SYNDROME

Resumen de: US2025262320A1

This disclosure relates to mRNA therapy for the treatment of Crigler-Najjar Syndrome Type 1 (CN-1). mRNAs for use in the invention, when administered in vivo, encode uridine diphosphate glycosyltransferase 1 family, polypeptide A1 (UGT1A1). mRNA therapies of the disclosure increase and/or restore deficient levels of UGT1A1 expression and/or activity in subjects. mRNA therapies of the disclosure further decrease abnormal accumulation of bilirubin associated with deficient UGT1A1 activity in subjects.

Circular RNA Compositions

Resumen de: US2025262324A1

Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treatment, including for cancer and autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder, a HER2 binder, or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.

INJECTABLE SHEAR-THINNING HYDROGEL CONTAINING THERAPEUTIC AGENT FOR ENHANCED TUMOR THERAPY

Resumen de: US2025262231A1

We have developed novel shear-thinning biomaterials using silica nanoparticles, gelatin-based polymers and small molecules such as doxorubicin. Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up.

NUCLEIC ACID NANOSTRUCTURES CROSSLINKED WITH OLIGOLYSINE

Resumen de: US2025262311A1

The present disclosure provides, in some aspects, nucleic acid nanostructures covalently linked to oligolysine-PEG copolymers.

DELIVERY COMPOSITIONS

Resumen de: WO2025174825A2

This disclosure provides, for instance, novel lipids suitable for use in lipid nanoparticles, for therapeutic delivery of nucleic acids. Also provided are methods of making and using the lipids.

NANOPARTICLES COMPRISING ENZALUTAMIDE

Resumen de: US2025262166A1

The invention relates to nanoparticles comprising Enzalutamide, processes for the preparation of such nanoparticles, pharmaceutical compositions and pharmaceutical dosage forms comprising such nanoparticles, processes for the preparation of such pharmaceutical dosage forms, and uses of the pharmaceutical dosage forms for medical purposes.

COMPOSITIONS OF KINETIC NANOPARTICLES CONTAINING NUCLEIC ACIDS, POLYCATIONS, AND LIPIDS WITH DEFINED SIZES, AND METHOD OF PRODUCING THE SAME

Resumen de: US2025262156A1

Hybrid nanoparticles having a defined size in a range between about 50 nm to about 1000 nm prepared by a kinetic assembly process are disclosed. The hybrid nanoparticles comprise a biodegradable polycation and a PEGylated lipid and include a nucleic acid including, but not limited to, plasmid DNA, messenger RNA (mRNA), small interfering RNA (siRNA), and the like. The assembled hybrid nanoparticles can be used for gene delivery therapy in vivo through various delivery routes and ex vivo and in vitro to transfect cells of interest. The disclosed hybrid nanoparticles with certain sizes within a sub-micron range exhibited significantly improved transfection efficiency compared to nanoparticles without size control.

NANO-IN-MICRO ENCAPSULATED siRNA DRY POWDER, METHOD FOR PRODUCING THE SAME AND USE OF A POWDER FORMULATION

Resumen de: US2025262158A1

Method for producing high yield nano-in-micro (NIM) encapsulated bioactive siRNA dry powder comprising the steps of: —providing an aqueous suspension comprising polyplexes, in particular polyelectrolyte complexes, formed from at least a polyamine, and/or polyamide and/or polyester and siRNA, wherein the polyplexes are provided with and/or encapsulated into water soluble excipients, in particular highly purified water and/or sugar alcohol and/or sugar; —spray drying the aqueous suspension using a spray In drying apparatus, preferably a Büchi B-290, by feeding the aqueous suspension to a spray drying atomizing nozzle and subjecting the atomized droplets to a heated gas stream of a carrier gas, preferably dried and cleaned air, in particular through a multicomponent atomizing nozzle for the suspension and an atomizing gas; —collecting a spray dried powder in an accumulation means of the spray drying apparatus characterized in that the temperature in the vicinity of an outlet opening of the spray drying apparatus, in particular an outlet opening connecting a spray drying chamber with the accumulation means, during feeding of the aqueous suspension to the nozzle is controlled by temperature controlling means to be limited to an upper threshold temperature which is equal to or below a melting temperature of the respective naked siRNA.

PLATFORM NANOPARTICLE TECHNOLOGY FOR SUSTAINED DELIVERY OF HYDROPHOBIC DRUGS

Resumen de: US2025262146A1

This invention relates to a nanogel platform technology that can increase the water solubility of hydrophobic compounds, particularly hydrophobic compounds having one or more double bonds, by more than about 400 fold. Methods according to embodiments of the invention involve copolymerizing the hydrophobic compound with N-isopropylacrylamide monomer and dextran-lactate-2-hydroxyethyl-methacrylate macromer via UV emulsion polymerization in aqueous solution. The resulting nanosystem has the additional advantage of being able to sustain the release of the drug candidate for a long period of time, thus increasing the half-life, long-term bioavailability and therapeutic effects of these hydrophobic compounds.

NANOEMULSION COMPRISING DICLOFENAC

Resumen de: US2025262178A1

A nanoemulsion for topical drug delivery, comprising diclofenac alkali metal salt, diclofenac free acid, a solvent of the glycol, or glycol ether or glycol ether ester family, a nonionic surfactant with a hydrophilic lipophilic balance (HLB) value of about 14-16, caprylic capric triglyceride, and water. The nanoemulsion is useful in the treatment of joint pain, osteoarthritis, muscle pain, back pain and/or inflammation.

LIPID NANOPARTICLES COMPRISING CODING RNA MOLECULES FOR USE IN GENE EDITING AND AS VACCINES AND THERAPEUTIC AGENTS

Resumen de: WO2025174765A1

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.

CATIONIC LIPID COMPOUNDS FOR USE IN LIPID NANOPARTICLES

Resumen de: WO2025174858A1

The present disclosure provides cationic lipid compounds having the following Structure (I): where G1, G2, R1, R2, R3a, R3b, R3c, R3d, R4a, R4b, R4c, R4d, L1, L2, and L3 are as defined herein. The present disclosure also discloses pharmaceutically acceptable salts or stereoisomers thereof. Also provided by the present disclosure are uses of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

COMPOSITIONS OF A THERAPEUTIC POLYENE MACROLIDE AND METHODS OF THEIR USE

Resumen de: WO2025172861A2

This invention relates to compositions including acid addition salt formulations including a compound of formula (I). Also disclosed are methods of their use and preparation.

LIPIDS FOR NANOPARTICLE DELIVERY PLATFORM

Resumen de: WO2025172284A1

The present disclosure includes ionizable lipids suitable for lipid nanoparticle compositions and pharmaceutical formulations thereof. The lipids have general formula (I).

Small Highly Uniform Nanomedicine Compositions For Therapeutic, Imaging And Theranostic Applications

Resumen de: AU2025213607A1

A targetable nanoconstruct capable of simultaneously serving as a therapeutic platform for photodynamic therapy as well as an MR molecular imaging agent, free of heavy metal atoms. F3-cys targeting agent nanoconstructs, including 8PEGA-Ce6 NCs. A label-free 8PEGA nanoconstruct that can be directly and selectively imaged by MRI, using standard spin-echo imaging sequences with large diffusion magnetic field gradients to suppress the water signal. A targetable nanoconstruct capable of simultaneously serving as a therapeutic platform for photodynamic therapy as well as an MR molecular imaging agent, free of heavy metal atoms. F3-cys targeting agent nanoconstructs, including 8PEGA-Ce6 NCs. A label-free 8PEGA nanoconstruct that can be directly and selectively imaged by MRI, using standard spin-echo imaging sequences with large diffusion magnetic field gradients to suppress the water signal. ug t a r g e t a b l e n a n o c o n s t r u c t c a p a b l e o f s i m u l t a n e o u s l y s e r v i n g a s a t h e r a p e u t i c u g p l a t f o r m f o r p h o t o d y n a m i c t h e r a p y a s w e l l a s a n m o l e c u l a r i m a g i n g a g e n t , f r e e o f h e a v y m e t a l a t o m s - c y s t a r g e t i n g a g e n t n a n o c o n s t r u c t s , i n c l u d i n g - e s l a b e l - f r e e n a n o c o n s t r u c t t h a t c a n b e d i r e c t l y a n d s e l e c t i v e l y i m a g e d b y , u s i n g s t a n d a r d s p i n - e c h o i m a g i n g s e q u e n c e s w i

ANTIGEN-CAPTURING NANOPARTICLES AND FORMULATIONS FOR IMMUNOTHERAPY

Resumen de: AU2024219072A1

The present invention provides novel antigen-capturing nano-particles (ACNPs) and pharmaceutical formulations containing such ACNPs. Also provided herein are methods for preparing the ACNP formulations, and methods for the treatment of a disease (such as cancer) in a subject with the ACPNs or a pharmaceutical formulation containing the ACPNs.

AMINO LIPID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: AU2024208147A1

An amino lipid compound, and a preparation method therefor and the use thereof. The present invention further relates to a lipid nanoparticle and a pharmaceutical composition containing the amino lipid compound, and the use thereof.

COMPOSITIONS AND METHODS FOR TREATING PULMONARY CONDITIONS

Resumen de: AU2024213596A1

A method of treating a pulmonary condition in a subject having or at risk of having the pulmonary condition generally includes administering to the subject a therapeutic composition in an amount effective to treat the pulmonary' condition. Generally, the therapeutic composition includes purified exosome product (PEP) exosomes and a pharmaceutically acceptable carrier. In one or more embodiments, the PEP exosomes are modified to include at least one exogenous active agent. In one or more embodiments, the therapeutic composition is formulated for delivery directly to a potion of tire pulmonary tract.

"Good" buffer-based cationic lipids

Resumen de: US2025263385A1

The present invention provides, in part, second generation “good” buffer-based cationic lipids of Formula (I), and subformulas thereof: Formula (I), (t), or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

SELENIUM NANOPARTICLES FOR USE IN PREVENTING, REDUCING RISK OF DEVELOPING OR TREATING EPILEPSY IN A SUBJECT IN NEED THEREOF

Resumen de: WO2025171862A1

Selenium nanoparticles for use in preventing, reducing risk of developing or treating epilepsy in a subject in need thereof, wherein selenium nanoparticles are administered parenterally to the subject, together with a transient disruption of the blood-brain barrier (BBB) of the subject.

SYNTHESIS OF CHIMERIC PEPTOSOMES HYBRIDIZED WITH ROD-SHAPED GOLD NANOPARTICLES AND APTAMER-TARGETED FOR BREAST CANCER THERAPY AND IMAGING

Resumen de: WO2025172829A1

The invention focuses on creating chimeric peptosomes combined with gold nanoparticles and fitted with aptamers for targeted therapy and imaging of breast cancer. It aims to solve the problem of effectively targeting breast cancer cells without harming healthy cells. The method uses a special polypeptide made of polyethylene glycol (PEG) and poly(γ-benzyl L-glutamate) (PGBLG) to form a peptosome with a strong core for containing the chemotherapy drug doxorubicin. The peptosome is designed for controlled release of the drug and also allows for the inclusion of gold nanoparticles. The EpCAM aptamer is used to target cancer cells more precisely, improving therapy effectiveness and imaging through the unique properties of gold nanoparticles. This new platform enhances treatment success while minimizing side effects, representing a major advance in targeted cancer therapy.

金属－リン脂質複合体、金属－リン脂質複合体粒子及び薬物－脂質粒子、並びにその製造方法及び応用

Resumen de: MX2025001257A

Provided are a metal-phospholipid complex, a metal-phospholipid complex particle, a drug-lipid particle, a method for preparing same, and use thereof, which relate to the field of biotechnology. The metal-phospholipid complex is formed by reacting a phospholipid molecule portion, a linker molecule portion and a metal ion portion. The metal-phospholipid complex particle comprises the metal-phospholipid complex, a conjugated lipid that inhibits particle aggregation, and a non-cationic lipid or a non-ionizable lipid. The drug-lipid particle comprises a drug and the metal-phospholipid complex particle. The metal-phospholipid complex is used for adsorbing a drug with negative charges, and is self-assembled with other components to form the metal-phospholipid complex particle (MPP); the cationic lipid and the ionizable lipid are not used under the condition of being not lower than the effectiveness of the LNP based on the cationic lipid and/or the ionizable lipid; compared to the LNP, the toxicity is greatly reduced, and the biological safety is significantly improved, thereby better facilitating carry of negative-charge drugs in an organism.

ＬｉｎｃＲＮＡ－ｐ２１およびその使用

Resumen de: TW202508605A

The present invention provides a composition for treating cancer comprising a DDB2 inhibitor and a chemotherapeutic agent, in which the DDB2 inhibitor comprises three RNA fragments from lincRNA-p21. In addition, the DDB2 inhibitor enhances the chemosensitivity of the cancer to the chemotherapeutic agent for treating cancers that do not respond to chemotherapy.

ＲＮＡカプセル化の定量的評価

Resumen de: CN119947710A

The present invention relates to a method for determining the efficiency of RNA encapsulation in lipid nanoparticles (LNPs). In some embodiments, a method according to the invention comprises the steps of a) contacting a sample comprising RNA encapsulated in LNP with a first fluorophore and a second fluorophore, thereby forming a fluorophore-RNA complex, and b) detecting a fluorescence signal of the complexed first and second fluorophore, wherein the first fluorophore permeates the LNPs and wherein the second fluorophore does not permeate the LNPs.

療法、特に抗癌療法での使用に適した磁性ポリマーナノカプセル

Resumen de: WO2024033546A1

Magnetic polymer nanocapsules and their use in anti-cancer therapy have been disclosed, which are core-shell polymer nanocapsules carrying hydrophobic active substances, containing magnetic iron oxide nanoparticles.

MICELLAR NANOPARTICLES AND USES THEREOF

Resumen de: EP4603589A2

The present disclosure includes cationic carrier units comprising (i) a water soluble polymer, (ii) a positively charged carrier, and (iii) an adjuvant moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.

LIPID-POLYMER COMPOUNDS, COMPOSITIONS, AND USES THEREOF

Resumen de: WO2024081668A2

Described herein are compounds comprising a lipid connected to a backbone of a polymer with functional groups. Also described herein is the use of such reagents for delivering nucleic acids to a cell.

A FORMULATION FOR ORAL DELIVERY OF PEPTIDES AND BIOSIMILARS FOR SYSTEMIC ABSORPTION AND METHOD OF MANUFACTURING THE SAME

Resumen de: WO2024079756A2

The invention relates to formulation for oral delivery of peptides and/or drug molecules and a method of manufacturing the same. The oral formulation is useful for delivering peptides to the gastrointestinal tract, preferably at the ileo-caecal junction of colon.

NOVEL TUMOR-SPECIFIC ANTIGENS FOR MYELOID LEUKEMIA AND USES THEREOF

Resumen de: WO2024077376A1

Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of myelodysplastic syndrome (MDS) or leukemia such as AML is also described.

MODIFIED OLIGONUCLEOTIDES

Resumen de: AU2023360051A1

The invention relates to oligonucleotides that inhibit Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8), or potentiate TLR8, and uses thereof.

HUMAN SERUM ALBUMIN BASED NANOCARRIERS FOR TARGETED IMMUNOTHERAPY

Resumen de: EP4603108A1

The present invention relates to a mannose-HSA based nanocarrier system, and a pharmaceutical composition containing the same for delivery of immunomodulatory drugs into target cells expressing surface mannose receptors. The present invention further relates to a method of manufacturing said mannoseHSA nanocarrier system.

LIPIDIC NANOPARTICLES COMPRISING AN ENCAPSULATED DRUG AND METHOD OF PRODUCING THE SAME

Resumen de: WO2024095144A1

The present application relates to lipidic nanoparticles that are suitable for the treatment of neurologic or chronic diseases. The lipidic nanoparticles of the present application are of the solid lipid nanoparticles or nanostructured lipid carriers and comprise an encapsulated drug with a sustained and controlled drug delivery in the treatment of neurologic or chronic diseases.

NOVEL IONIZABLE LIPIDS

Resumen de: MX2025004314A

The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.

LIPID NANOPARTICLE FORMULATIONS FOR MRNA DELIVERY TO LANGERHANS CELLS

Resumen de: AU2023361222A1

The present invention relates to pharmaceutical compositions comprising at least one lipid nanopartide (LNP) specific for targeting Langerhans cells (LC) wherein the LNP encapsulates at least one mRNA, is capable of specifically binding to the receptor Langerin and facilitates Langerin-mediated uptake and intracellular delivery of said mRNA molecule and its translation into at least one protein or peptide. Further envisaged is the pharmaceutical composition for use in the treatment of cancer, of an autoimmune disease, of a bacterial infection, of a viral infection, of a fungal infection or of a graft-vs. host disease, of a local or systemic inflammation, of an allergy, or for hyposensitization.

脂質封入ＲＮＡナノ粒子の製造方法

Resumen de: US2025177305A1

A method of producing a lipid-encapsulated RNA nanoparticle, comprising the steps a) flowing an aqueous solution comprising an RNA through a 1st tube having an inner diameter (ID) of between about 0.1″ and 0.132″; b) flowing an ethanol solution comprising lipids through a 2nd tube having an ID of between about 0.005″ and 0.02″ at one third the flow rate of the aqueous solution through the 1st tube, wherein the lipids comprise a cationic lipid; and c) mixing the ethanol solution with the aqueous solution by flowing the ethanol solution and the aqueous solution into a mixing module consisting of the 2nd tube perpendicularly joined to the 1st tube; wherein the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about 10% to 75% ethanol v/v, and wherein the lipid-encapsulated RNA nanoparticles have a bilayer structure.

両親媒性オリゴエチレングリコール（ＯＥＧ）コンジュゲート化合物を含む核酸組成物およびそのような化合物および組成物を使用する方法

Resumen de: CN119654167A

The present disclosure relates generally to the field of nucleic acid (e.g., DNA or RNA, particularly mRNA) compositions comprising amphiphilic oligomeric ethylene glycol (OEG) conjugated compounds (as substitutes for PEG lipids); uses of such compositions, in particular for delivering nucleic acids to cells of a subject or for therapy; to an amphiphilic OEG conjugated compound of this type; and conjugates of such amphiphilic OEG conjugated compounds.

金属－ポリフェノール複合体粒子、薬物－脂質粒子、並びにその製造方法及び応用

Resumen de: WO2024032482A1

The present disclosure relates to the technical field of biopharmaceutics, and particularly provides a metal-polyphenol compound particle, a drug-lipid particle, a method for preparing same, and use thereof. The metal-polyphenol compound provided in the present disclosure serves as a drug carrier for drug stabilization, delivery and transportation and the like, and forms, together with other carriers, the metal-polyphenol complex particle for achieving effective administration of negatively-charged drugs. The complex can achieve efficient systemic drug delivery and, compared with LNP containing cationic lipids or ionizable lipids, has significantly reduced toxicity, achieving safe and effective treatment of diseases or conditions.

Composiciones de nanopartículas lipídicas

Resumen de: US2025090471A1

The disclosure provides lipid nanoparticle (LNP) compositions of ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.

一种基于CMCS封装性多孔金纳米壳对紫杉醇的增溶方法

Resumen de: CN120501719A

本发明涉及药物制剂技术领域，尤其涉及基于CMCS封装的多孔金纳米壳在紫杉醇药物输送上的应用。本技术方法为将通过CMCS封装的多孔金纳米壳作为紫杉醇药物的载体，从而能够在使用时实现对PTX的pH响应性释放。本发明提供的基于CMCS封装性多孔金纳米壳在紫杉醇药物输送上的应用，将多孔金纳米壳与紫杉醇药物混合，并通过CMCS进行封装形成的CMCS/PTX/EHGNs，能够在癌症治疗时提升其水溶性和生物利用度。

一种载有酚醛网络的白蛋白纳米粒子的制备方法及应用

Resumen de: CN120501722A

本发明适用于生物医药技术领域，提供了一种载有酚醛网络的白蛋白纳米粒子的制备方法及应用。本发明通过将表没食子儿茶素没食子酸酯‑铜(EGCG‑Cu)金属酚醛网络(EC NPs)负载于牛血清白蛋白纳米粒子(BSANPs)内，构建了一种智能纳米输送体系(BEC NPs)。该体系可特异性靶向炎症部位中性粒细胞，响应炎症微环境释放EC NPs，通过清除活性氧、抑制中性粒细胞外陷阱形成、促进巨噬细胞向M2型极化、抑制细胞焦亡等机制改善炎症微环境，缓解炎症损伤。体内实验显示BEC NPs能促进牙槽骨再生和牙周组织修复，生物相容性良好，为慢性牙周炎提供了兼具抗炎、免疫调控和组织修复功能的纳米治疗策略。

一种环状多倍串联RNA正义链

Resumen de: CN120505342A

本发明提供了一种环状多倍串联RNA正义链，其包括至少一个正义链序列和至少一个间隔序列。该环状RNA衍生自含有所有必需序列的工程化亲本DNA模板，其按以下顺序包括第一环化元件、任选地至少一个第一限制性酶识别序列、至少一个靶序列、任选地至少一个第二限制性酶识别序列和第二环化元件。该环状多倍串联RNA正义链可以结合并递送多个反义链RNA，在利用环状RNA稳定性优势的同时增加正义链和反义链的结合。

一种药物组合物及其应用

Resumen de: CN120501756A

本发明公开了一种药物组合物，其包含环状RNA以及药物递送载体。与传统线性1×siRNA和环状1×siRNA相比，本公开将正义链重复串联数量增加到包括但不限于2个以上，意外地发现显著增强了沉默效果，能够显著降低PCSK9基因的表达水平，介导PCSK9蛋白的mRNA的降解。使用纳米颗粒递送寡核苷酸，增加了稳定性，降低了免疫原性，提高了降胆固醇、减少主动脉斑块负荷、抗动脉粥样硬化的作用，且安全无明显肝肾毒性，在制备高胆固醇血症、冠心病的治疗药物方面具有广阔的应用前景。

食品级乳液纳米颗粒联合自噬抑制剂在制备抗肿瘤药物中的应用

Resumen de: CN120501721A

本发明属于生物医药及纳米技术领域，具体公开了食品级乳液纳米颗粒联合自噬抑制剂在制备抗肿瘤药物中的应用，所述食品级乳液纳米颗粒是以大豆油为基础油相，单甘油脂为乳化剂，PBS为水相混合制成的乳液纳米颗粒FLNs；所述自噬抑制剂为3‑MA。本发明利用“撑死”肿瘤细胞的策略，采用食品级乳液纳米颗粒FLNs联合自噬抑制剂3‑MA瘤内注射，实现皮下异质瘤生长及转移的有效抑制，且未发现任何明显的毒副作用，有望开发为一种基于瘤内注射的安全高效抗肿瘤策略。

一种靶向型白蛋白球形核酸药物及其制备方法和使用方法

Resumen de: CN118986929A

The invention belongs to the field of research and development of tumor drugs, and provides a targeted albumin spherical nucleic acid drug for delivering a hydrophobic drug, aiming at solving the problems that the existing traditional albumin drug is poor in targeted enrichment, strong in systemic side effect and the like, and the targeted albumin spherical nucleic acid drug is characterized in that a hydrophobic molecule is wrapped in albumin (HSA), and meanwhile, the hydrophobic molecule is used as a spherical nucleic acid drug for delivering the hydrophobic drug. Albumin with a plurality of hydrophobic structural domains on the surface and a plurality of aptamer sequences (Apt) with hydrophobic groups at the 5'end are mutually non-covalently modified and combined through hydrophobic interaction to form a spherical nucleic acid structure, and the aptamer has specific targeting property. The invention also provides a preparation method and a use method of the spherical nucleic acid medicine. The drug provided by the invention has excellent targeting property and stability, can realize specific targeting delivery of different types of tumors, improves the treatment effect of the drug, reduces toxic and side effects, and is suitable for large-scale industrial application.

一种环状RNA的制备方法

Resumen de: CN120505341A

本发明提供了一种环状RNA的制备方法，包括：使用包含至少一种RNA聚合酶启动子和核酸构建体的表达载体转化宿主细胞，其中所述核酸构建体按以下顺序从5’到3’的方向包括第一环化元件、任选地至少一个第一限制性酶识别序列、至少一个靶序列、任选地至少一个第二限制性酶识别序列和第二环化元件。该方法得到的环状RNA产量高，免疫原性低，可以结合并递送多个反义链RNA。

一种乌力地格抑菌凝胶及其制备方法

Resumen de: CN120501702A

本发明涉及妇科抑菌凝胶技术领域，具体涉及一种乌力地格抑菌凝胶及其制备方法；按重量份计包括以下组分：醋酸氯己定1‑3份、梅花草提取物4‑8份、卡波姆0.8‑1.2份、三乙醇胺0.4‑0.6份、促渗剂0.5‑1.5份、改性纳米银0.04‑0.07份、甘油5‑8份、氢化聚异丁烯0.03‑0.07份、依地酸二钠0.1‑0.3份和纯化水余量，本发明采用醋酸氯己定与梅花草乙醇提取物以1：(2.5‑4)的比例复配，梅花草中的黄酮和多酚类物质可破坏微生物细胞膜通透性，促进醋酸氯己定进入菌体内部，显著降低最小抑菌浓度。

一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用

Resumen de: CN120484249A

本发明属于生物医药技术领域，公开了一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用。本发明的所述含氟修饰聚肌氨酸化脂质具有如式(I)或式(II)所示结构通式。通过不同含氟基团化学改性聚肌氨酸化脂质得到的含氟修饰聚肌氨酸化脂质可以替代PEG化脂质制备脂质纳米颗粒(LNP)，用于负载核酸等药物，达到提升药物递送性能的目的。

用于成纤维细胞生长因子受体3介导的至星形胶质细胞的递送的组合物及方法

Resumen de: AU2023379457A1

The present invention provides, in part, protein-drug conjugates comprising an anti-fibroblast growth factor receptor 3 (FGFR3) (e.g., human FGFR3) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, polypeptides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain). Methods for treating various diseases or disorders, such as neurological diseases, with the conjugates are provided.

基于冷萃酶解高温换能技术的骨筋粘膜多靶点复合制剂的制备方法

Resumen de: CN120478581A

本发明公开了基于冷萃酶解高温换能技术的骨筋粘膜多靶点复合制剂的制备方法，涉及医药技术领域。本发明包括以下步骤：步骤一：原料预处理：选用新鲜、无污染的鳕鱼皮和鹿筋作为主要原料，将鳕鱼皮洗净，去除表面的杂质和脂肪，切成边长约0.5‑1cm的小块，鹿筋用30‑40℃温水浸泡12‑15小时进行泡发。本发明通过独特的4‑15℃低温阶段、15‑37℃阶梯升温阶段和脉冲热处理，有效避免了传统热提取对胶原蛋白等热敏性成分的破坏，保留了原料的天然活性，在低温阶段，温和的酶解条件能使原料中的热敏性物质得以完整保留，脉冲热处理则使胶原肽构象转换率提高，显著提升了其生物利用度和活性，更利于人体吸收和利用。

一种DACe@ET纳米药物的制备方法及其应用

Resumen de: CN120478400A

本发明提供了一种DACe@ET纳米药物的制备方法及其应用，制备方法，包括以下步骤：合成金纳米颗粒、金/二氧化铈核核壳结构纳米颗粒、修饰氨基聚乙二醇马来酰亚胺和星形胶质细胞归巢肽DAG；将星形胶质细胞归巢肽DAG和ET‑18‑OCH3加入金/二氧化铈核核壳结构纳米颗粒的溶液中，离心得到DACe@ET纳米药物；DACe@ET纳米药物在脑淀粉样血管病的治疗中的应用，能够调节氧化还原平衡和降低脑内铁沉积；本发明的DACe@ET纳米药物通过提高抗氧化能力，并改善细胞摄取能力，从而提高药物的生物利用度；可有效减少CAA模型小鼠脑内铁的异常积累，恢复脑内氧化还原平衡，表明其具有优异的脑铁稳态调控能力。

具格兰氏阴性菌抗菌活性的螯合型复合胶束及其应用

Resumen de: WO2024153108A1

The present invention discloses a chelating complex micelle presenting antimicrobial activity against gram-negative bacteria. The chelating complex micelle comprises metal ions, polymers having a chelating segment, and an antimicrobial agent having at least one Lewis base functional group, wherein the antimicrobial agent presenting antimicrobial activity against multi-drug-resistant gram-negative bacteria (MDR-GNB), such as carbapenem-resistant A. baumannii, P.aeruginosa, or Enterobacteriaceae.

一种大孔牛血清白蛋白纳米颗粒及其制备方法和用途

Resumen de: CN120478305A

本发明涉及一种大孔牛血清白蛋白纳米颗粒及其制备方法和用途，其中所述大孔牛血清白蛋白纳米颗粒为表面分布有大孔的纳米颗粒，所述纳米颗粒的尺寸范围为300~645nm，所述大孔为孔径范围为50~100nm的贯穿孔；所述纳米颗粒为对称N面体或球形纳米颗粒，其中N≥12。其比表面积高达20‑60m²/g，显著提升了药物负载能力（5‑25% w/w）与包封效率（50‑90%），较传统表面无孔的纳米颗粒吸附效率大大提升。与表面无孔的BSA纳米颗粒相比，大孔的存在提高了RhB的吸收效率，在药物递送方面具有广泛应用。

表达布鲁氏菌多抗原的混合疫苗及其制备方法和应用

Resumen de: CN120478610A

本发明属于生物医药技术领域，具体涉及一种表达布鲁氏菌多抗原的混合疫苗及其制备方法和应用，所述混合疫苗由脂质纳米颗粒对活性mRNA包封后获得；所述活性mRNA的核苷酸序列如SEQ ID NO.1~SEQ ID NO.8所示中的至少一种。本发明通过利用LNP独立包封编码布鲁氏菌8种关键抗原的mRNA制备所述混合疫苗。本发明所述的混合疫苗，不仅避免了抗原竞争问题，能够高效的被递送至免疫系统，且每种抗原都能引发均衡的免疫反应。

多叔胺多尾链可电离阳离子脂质、包含其的组合物及用途

Resumen de: CN120483890A

本公开属于医药领域，更具体地，涉及递送脂质技术领域，公开了多叔胺多尾链可电离阳离子脂质、包含其的组合物及用途。本公开提供的多叔胺多尾链可电离阳离子脂，其包括如式(I)所示的结构，可用于核酸靶向递送，能够显著增强mRNA疫苗或药物的防脱靶效应。#imgabs0#

一种水溶性自组装的壳聚糖纳米复合物及其制备方法与应用

Resumen de: CN120478651A

本发明公开了一种水溶性自组装的壳聚糖纳米复合物及其制备方法，所述纳米复合物由季铵盐化壳聚糖（O‑HTCC）与5β‑胆烷酸通过共价偶联形成两亲性聚合物NCH复合物，该纳米颗粒的粒径110±8.48 nm，包裹Alda‑1可有效提高Alda‑1的溶解度，包封率36.1%，显著降低DCD供肾移植后IRI损伤，提高线粒体ALDH2活性，使大鼠移植后3天血清肌酐下降至最低水平。本技术适用于离体器官机械灌注液改良，具有临床转化潜力。

用于治疗剂的靶向递送的自组装脂质纳米颗粒

Resumen de: MX2025005244A

The present invention provides delivery system compositions comprising self- assembling lipid nanoparticles for targeted delivery of therapeutic or diagnostic agents to target cells. The particles are non-covalently attached to a lipidated antibody or antibody fragment which comprises an antibody or antibody fragment attached, via a peptide linker, to a lipidated peptide portion, wherein the antibody or antibody fragment is at the distal end from the nanoparticle.

一种巨噬细胞-聚合物脂质纳米粒复合递药系统及其制备方法与其在抗隐球菌感染中的应用

Resumen de: CN120478378A

本发明公开了一种巨噬细胞‑聚合物脂质纳米粒复合递药系统及其制备方法与其在抗隐球菌感染中的应用。所述递药系统以α‑亚麻酸(ALA)、高分子量壳寡糖(HCOS)、两性霉素B(AmB)为原料构建纳米粒AmB‑PLHNs，藉由巨噬细胞的吞噬作用将纳米粒负载于巨噬细胞内，构建AmB‑PLHNs@M1。AmB是临床治疗Cn感染的常用药物，但存在肾脏毒副作用以及无法转运进入中枢的问题。AmB‑PLHNs@M1由M1型巨噬细胞的透血脑屏障特性，携带AmB‑PLHNs转运入脑，增加药物入脑效率。结合巨噬细胞对隐球菌的吞噬，结合巨噬细胞的炎症免疫调节功能和载药纳米粒的抑菌作用，用于Cn中枢感染治疗，降低AmB的毒副作用。

がんにおけるフェロトーシス誘導剤としての高密度リポタンパク質様ナノ粒子

Resumen de: MX2022003239A

Disclosed herein are compositions and methods for treating a subject having cancer and other ferroptosis disorders with high density lipoprotein-like nanoparticles that induce ferroptosis.

癌のための新規抗原及びその用途

Resumen de: CN119816515A

Breast cancer is now the most common cancer in the world, and despite treatment progression in decades in the past, metastatic breast cancer is still a disease which cannot be cured. Novel tumor specific antigens (TSA) and tumor associated antigens (TAA) expressed by breast tumor cells are described herein. Synthetic long peptides, nucleic acids, compositions, cells, TCRs, antibodies, and vaccines derived from these TSAs and TAAs are described. The use of the TSA/TAAs, nucleic acids, compositions, antibodies, cells and vaccines for the prevention or treatment of breast cancer, including triple negative breast cancer (TNBC), is also described.

ＤＮＡ結合タンパク質を含む脂質ナノ粒子

Resumen de: AU2023326249A1

The present disclosure relates to lipid nanoparticles for delivery of DNA, the lipid nanoparticle comprising therein a DNA-binding protein or peptide bound to the DNA, and uses thereof.

核酸の送達のための硫黄含有化合物及びその組成物

Resumen de: WO2024035783A2

Lipid nanoparticle compositions (LNPs), methods for preparing the LNPs, methods of using the same, including, but not limited to, for treatment of certain diseases and disorders, including, but not limited to liver disorders, kits for the delivery of nucleic acids to various types of cells, including T-cells and hepatocytes, in vivo, ex vivo and in vitro.

ステロール系イオン化脂質及びそれを含む脂質ナノ粒子

Resumen de: CN119816292A

Compounds, compositions, and methods for delivering therapeutic, diagnostic, or prophylactic agents (e.g., nucleic acids) are described.

免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法

Resumen de: AU2023321906A1

Provided herein are compositions and methods related to compositions comprising an Ig protease fusion protein. Also provided herein are compositions and methods for therapeutic treatment, such as of autoimmune diseases, allergies, or other immunological disorders, or in combination with the administration of another therapeutic, with such Ig protease fusion protein.

一种三重协同调控的多功能复合纳米酶的制备方法

Resumen de: CN120478633A

本发明适用于生物医学技术领域，提供了一种三重协同调控的多功能复合纳米酶的制备方法，该方法构建了一种基于三重环境自适应调控机制的智能纳米酶体系AgAu C‑L。该体系通过AgAu纳米笼的光热效应精准优化催化反应温度，同时结合罗伊氏乳杆菌的益生菌代谢特性主动降低局部pH至CeO2最佳活性范围，并协同AgAu@CeO2异质结界面电子转移优化策略增强电荷传递效率，三者共同作用显著提升CeO2纳米酶在生理中性/弱碱性环境下的催化效能，特别是其过氧化物酶样活性。该智能体系不仅能高效物理清除牙周致病菌生物膜，更能通过精准干扰病原菌核苷酸合成与精氨酸代谢等关键通路瓦解微生物协同网络，最终实现口腔微生态平衡的重塑。

一种双靶向仿生水滑石无机纳米颗粒及其制备方法和应用

Resumen de: CN120478303A

本发明涉及一种双靶向仿生水滑石无机纳米颗粒及其制备方法和应用，包括：获取新鲜红细胞膜；获取衰老红细胞膜；将新鲜红细胞膜和衰老红细胞膜以一定的比例加入水滑石无机纳米颗粒中进行混合搅拌，离心得到仿生水滑石无机纳米颗粒。本发明的有益效果是：本发明双靶向仿生水滑石无机纳米颗粒具有平衡递送至肝实质细胞和肝巨噬细胞的双靶向能力，可同时缓解氧化应激和炎症反应。

一种多功能纳米复合材料的制备方法及其应用

Resumen de: CN120478306A

本发明适用于生物医学技术领域，提供了一种多功能纳米复合材料的制备方法及其应用。该材料生物相容性良好，可作为安全制剂用于肿瘤治疗；制备简便且绿色无污染；扩展了槲皮素在抗肿瘤免疫治疗中的应用；具有优异的荧光/计算机断层扫描双模式成像性能，可用于确定肿瘤边界，实现精准治疗引导；具有优良的光热及光热增强的催化性能，具备微创高效、毒副作用小且可控等优势，能通过激活免疫有效治疗原发、转移或复发性头颈部鳞状细胞癌；通过诱导肿瘤细胞释放2’3’‑cGAMP并防止其降解，高效激活cGAS‑STING信号通路，最终增强抗肿瘤免疫效果。

一种mRNA脂质纳米粒及其制备方法和应用

Resumen de: CN120478287A

本发明涉及纳米生物技术领域，提出了一种mRNA脂质纳米粒及其制备方法和应用。该mRNA脂质纳米粒，通过透明质酸酶（HAase）修饰以降解肿瘤细胞外基质中的透明质酸，改善肿瘤微环境，降低肿瘤组织的屏障作用，从而增强mRNA‑LNP的渗透性。此外，该体系在肿瘤微酸环境下可发生粒径翻转，提高肿瘤深层细胞的递送效率。实验结果表明，该递送体系可有效提高mRNA在肿瘤组织中的渗透能力和抗肿瘤疗效，为肿瘤基因治疗提供了一种新的策略。

呕吐毒素致断奶仔猪肠道铁死亡的抑制剂及制备方法

Resumen de: CN120478304A

本发明涉及畜牧技术领域，尤其涉及一种呕吐毒素致断奶仔猪肠道铁死亡的抑制剂及制备方法，本发明整合铁螯合剂(去铁胺，DFO)、GPX4激活剂(硒甲硫氨酸，SeMet)及抗炎成分(姜黄素、黄芪多糖、双氢青蒿素)，覆盖铁蓄积、GPX4失活、脂质过氧化等铁死亡三大核心通路；同时，采用pH敏感型壳聚糖‑海藻酸钠纳米颗粒对以上成分进行包被，使其能够过胃，避免受到胃酸的破坏，确保药物在肠道的碱性环境中精准释放，从而提高药物的利用率；并且，硒甲硫氨酸、姜黄素、黄芪多糖、双氢青蒿素均为天然来源，可以避免化学药物残留风险，可作为饲料添加剂应用于断奶仔猪当中。

METHOD FOR PRODUCING METAL OXIDE NANO-PARTICLES, AND METAL OXIDE NANO-PARTICLES

Resumen de: US2025256978A1

The present invention enables us to achieve both further fine particle size reduction and uniformity of particle size distribution of metal oxide nanoparticles.The present invention is a method for producing metal oxide nanoparticles that consists of a process for obtaining metal oxide nanoparticles by mixing a supercritical, subcritical, or gas phase aqueous material and an organometallic complex solution, wherein the mixing time is controllable within the range of 0.015 s to 380 s and the diameter of at least one of the average primary particle diameter or the crystallite diameter of the nanoparticles can be controlled within the range of 1.0 nm to 9.0 nm, and the coefficient of variation of the diameter can be controlled within 0.5 nm or less by controlling the mixing time. The resulting nanoparticles encompass metal elements capable of forming organometallic complexes. Additionally, the organic molecules are strongly bonded to the most unstable surface.

HYBRID NANOFIBROUS MAT AND METHOD OF MAKING SAME

Resumen de: WO2025166401A1

There is provided a hybrid nanofibrous mat comprising electrospun nanofibers formed by electrospinning of a polymer mix and porous silica capsules dispersed throughout the electrospun nanofibers during the electrospinning, the porous silica capsules having a hydrophobic liquid core containing an active. There is also provided a method of producing a hybrid nanofibrous mat comprising providing porous silica capsules having a hydrophobic liquid core containing an active, forming an electrospinning solution comprising the porous silica capsules and an electrospinning polymer mix, homogenising the electrospinning solution to fully disperse the porous silica capsules, and electrospinning the electrospinning solution to form the hybrid nanofibrous mat.

IMPROVED NANOCARRIER MANUFACTURING

Resumen de: US2025256248A1

An apparatus may be for producing nanocarriers and/or nanoformulations. A process may be for producing a nanocarrier and/or a nanoformulation with this apparatus. According to the preparation, a first liquid phase and a second liquid phase are mixed first to give a primary mixture using a static mixer. In a subsequence mixing step the primary mixture is diluted with a third liquid. An aspect of apparatus may be that the arrangement of the static mixer inside a linear pipe conducting a third liquid phase. Thus, the primary mixture exiting the mixer is instantaneously diluted with to give secondary mixture. The volume flow of the third mixture is chosen larger than the volume flow of the primary mixture. By these measures, nanocarriers with improved morphology and homogeneity are produced. Encapsulation efficiency was enhanced as well.

METHODS AND COMPOSITIONS RELATED TO TRNA THERAPEUTICS FOR TREATING VISION LOSS

Resumen de: US2025257354A1

Provided herein are compositions and methods related to tRNA therapeutics for treating vision loss and blindness.

DRUG-DELIVERY NANOPARTICLES AND TREATMENTS FOR DRUG-RESISTANT CANCER

Resumen de: US2025255978A1

Disclosed herein are compositions comprising nanoparticles comprising a carrier polypeptide and a double-stranded oligonucleotide, wherein the carrier polypeptide comprises a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment; and wherein the molar ratio of the carrier polypeptide to the double-stranded oligonucleotide in the nanoparticle composition is less than about 6:1, along with methods of making and using such nanoparticles. Further described are methods of treating a subject with a cancer, such as a chemotherapeutic drug resistant cancer comprising administering to the subject a composition comprising nanoparticles, the nanoparticles comprising a carrier polypeptide comprising a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment; a double-stranded oligonucleotide bound to the oligonucleotide-binding segment; and a chemotherapeutic drug bound to the double-stranded oligonucleotide. Also described are pharmaceutical compositions, articles of manufacture, and kits comprising the described nanoparticles.

MNO NANOMATERIAL BASED INHIBITORS OF INFLAMMATION AND CANCER METASTASIS

Resumen de: US2025255984A1

The anionic manganese oxide nanoparticle nucleic acid scavengers are biodegradable anionic scavengers with low cytotoxicity, which are able to scavenge (bind) cell-free nucleic acids (e.g., extracellular ssRNA, dsRNA, and unmethylated DNA), providing treatment for various medical conditions. The main component of the scavenger is manganese oxide, which may be synthesized by using a manganese compound (e.g., manganese acetate) and an acid (e.g., tannic acid) at high temperature (e.g., 100-150° C.). Synthesis may be performed by mixing a manganese compound and an acid in water forming a mixture, which is stirred, heated, and allowed to cool. The anionic manganese oxide nanoparticles are extracted from the cooled mixture. The typical size of the resultant nanomaterials ranges from 30 to 100 nm; the zeta potential of the as-prepared nanomaterials is about −20 mV. The nanoparticles have various uses, including administration to a subject to treat inflammation or to treat cancer.

COMPLEX

Resumen de: US2025255974A1

An object is to provide a technique that improves the poor solubility of a compound of formula (1) in water and further suppresses the cytokine excessive release action and bone marrow toxicity of the compound of formula (1). This object is achieved by a complex comprising a modified polysaccharide containing a hydrophobic group, and a compound represented by formula (1).

Multifunctional Nanoparticles and Uses in Managing Cancer and Cardiovascular Diseases

Resumen de: US2025255829A1

This disclosure relates to nanoparticles comprising a cardiovascular agent, a PD-L1 binding agent on the surface, and optionally an anticancer agent. In certain embodiments, the cardiovascular agent is an inhibitor of cholesterol acyltransferase such as avasimibe. In certain embodiments, the nanoparticles comprise a hyaluronic acid core. In certain embodiments, this disclosure relates to methods of treating or preventing cancer and/or atherosclerosis, or other cardiovascular disease by administering an effective amount of nanoparticles disclosed herein to a subject in need thereof.

ICE-BASED LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF MRNA

Resumen de: US2025255971A1

The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.

Peptide-Protected Gold Nanocluster and Uses Thereof

Resumen de: US2025255962A1

A gold nanocluster of the formula Au22(Lys-Cys-Lys)16, wherein Lys-Cys-Lys is lysine-cysteine-lysine, and methods for synthesis, are provided. The gold nanocluster effectively produces Type I ROS and functions as photosensitizer, and has utility in applications such as, but not limited to, biomedical applications and photocatalysis. The gold nanocluster may be useful in photodynamic therapy (PDT) and as a radiosensitizer in cells and tissues for treating diseases such as certain cancers.

PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS

Resumen de: US2025255850A1

Method and compositions that comprise an agent that reduces nNOS activity and uses thereof in the treatment of a disease or condition in which a beneficial clinical effect is achieved by reduction in neuronal nitric oxide synthase (nNOS) activity are provided.

FORMULATIONS COMPOSED OF CATIONIC LIPIDS AND POLY(LACTIC-CO-GLYCOLIC ACID) FOR THE DELIVERY OF POLYNUCLEOTIDES INTO CELLS

Resumen de: US2025255817A1

A nanoprecipitation or nanoemulsion method forms a polynucleotide delivery particle, wherein the polynucleotide delivery particle contains at least one poly(lactic-co-glycolide), at least one cationic surfactant, at least one polynucleotide, and optionally at least one additive, wherein the poly(lactic-co-glycolide) has a weight average molecular weight Mw of 1000 to 9500 g/mol measured via gel permeation chromatography using polystyrene standards and chloroform. The polynucleotide delivery particle as an additional component in an oral drug delivery composition or a parenteral drug delivery composition supports the beneficial characteristics of the application as a medicament.

POLYSULFIDE MICROPARTICLES AND USES THEREOF

Resumen de: US2025255816A1

Disclosed herein are polysulfide microparticles that include a varying monomer composition. The monomer composition can control properties of the microparticles, such as crystallinity, which can aid in the production and stability of the microparticles. An example microparticle includes a polymer derived from monomers of propylene sulfide (PS) and ethylene sulfide (ES). The microparticles disclosed herein can be useful in drug delivery applications, such as treating inflammatory diseases. Also disclosed are methods of making the polysulfides and methods of making the microparticles.

LYOPHILIZED LIPID NANOPARTICLES AND METHODS OF THEIR USE

Resumen de: US2025255828A1

The invention is directed to the field of therapeutic formulations, in particular to lyophilization of a therapeutic cargo molecule, such as RNA. The invention provides a method for lyophilization of a molecule. The present disclosure further describes a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine, a therapeutic and a kit or kit of parts. Moreover, the disclosure herein provides a novel lyophilization excipient that protects the composition from degrading when, for example, lyophilizing RNA. The use of the inventive method further includes the manufacture of a composition that can be used after lyophilization with equivalent therapeutic effect and composition integrity.

NUCLEIC ACIDS ENCODING A CONSTITUTIVELY-ACTIVE CYCLIC GMP-AMP SYNTHASE AND IMMUNOGENIC DELIVERY VEHICLES FOR SAME

Resumen de: US2025255815A1

The present disclosure relates to compositions for expression of a constitutively-active cyclic GMP-AMP synthase in cells of a mammalian subject and uses thereof for enhancing immunogenicity of mRNA vaccines. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising one or both of a lysophosphatidylcholine (LPC) compound and a pathogen recognition receptor agonist.

VAPOR PHASE COATING TECHNOLOGY FOR PHARMACEUTICAL ABUSE DETERRENT FORMULATIONS

Resumen de: US2025255831A1

A method of preparing an abuse deterrent pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. This produces an abuse deterrent pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials.

POLYMER-LIPID NANOCOMPLEX FOR ENHANCED AQUEOUS SOLUBILISATION AND ABSORPTION OF HYDROPHOBIC ACTIVE COMPOUNDS

Resumen de: US2025255825A1

The current invention relates to a polymer-lipid nanocomplex for enhanced aqueous solubilisation and absorption of hydrophobic active compounds, a process for producing such a nanocomplex, and to methods of use of such a nanocomplex.

NANOGEL PLATFORM TECHNOLOGY FOR LONG-TERM BIOLOGICS THERAPY

Resumen de: US2025255808A1

Biologics, including peptides, proteins, antibodies, nucleic acids (DNA and RNA), oligonucleotides, vaccines, or complex combinations of these substances, are important for treating various types of diseases and tissue and organ regeneration. However, biologics are not stable and have short half-lives, making effective delivery to patients difficult. Therefore, there is an unmet need in the art to increase the stability and half-lives of biologics for long-term bioavailability, therapy, treatment and repair. This invention provides a nanogel platform technology that can load biologics in aqueous solution with high loading efficiency without using any organic solvent and also sustain the release of active biologics in the body for more than 2 months.

BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS

Resumen de: US2025255830A1

A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.

IMPROVED PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES

Resumen de: AU2025208550A1

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process for enhanced encapsulation of messenger RNA (mRNA) in lipid nanoparticles comprising a step of heating the mRNA-encapsulated lipid nanoparticles in a drug product formulation solution. The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process for enhanced encapsulation of messenger RNA (mRNA) in lipid nanoparticles comprising a step of heating the mRNA-encapsulated lipid nanoparticles in a drug product formulation solution. ul h e p r e s e n t i n v e n t i o n p r o v i d e s a n i m p r o v e d p r o c e s s f o r l i p i d n a n o p a r t i c l e f o r m u l a t i o n u l a n d m e n c a p s u l a t i o n n s o m e e m b o d i m e n t s , t h e p r e s e n t i n v e n t i o n p r o v i d e s a p r o c e s s f o r e n h a n c e d e n c a p s u l a t i o n o f m e s s e n g e r ( m ) i n l i p i d n a n o p a r t i c l e s c o m p r i s i n g a s t e p o f h e a t i n g t h e m - e n c a p s u l a t e d l i p i d n a n o p a r t i c l e s i n a d r u g p r o d u c t f o r m u l a t i o n s o l u t i o n

METHOD FOR SYNTHESIZING ZEOLITE NANOPARTICLES IN A SALINE PHOSPHATE BUFFER AND ASSOCIATED NANOPARTICLES, SUSPENSIONS AND PHARMACEUTICAL COMPOSITION

Resumen de: AU2024248582A1

The present invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal according to which: - a first composition/solution 1 containing an aluminum source and a source of an ion of an alkali metal M, in particular K, is prepared; a second composition/solution 2 comprising a silicon source and a source of an ion of an alkali metal M, in particular K, is prepared, said compositions/solutions 1 and 2 being free of any organic structuring agent; - the two compositions/solutions 1 and 2 are mixed; - the mixture is crystallized; and - said nanoparticles thus formed are optionally separated. According to the invention, said first composition/solution 1 and said second composition/solution 2 are both constituted of said source and of the aqueous saline phosphate buffer. The present invention also relates to colloidal suspensions of the nanoparticles obtained and to a pharmaceutical composition containing said nanoparticles.

CLEAVABLE LINKER-CONTAINING IONIZABLE LIPIDS AND LIPID CARRIERS FOR THERAPEUTIC COMPOSITIONS

Resumen de: TW202438045A

The present disclosure relates to a lipid compound of formula (AL-GI):, having various cleavable linkers defined by the variables Z1 and Z2. The present disclosure also relates to a lipid carrier or lipid nanoformulation employing the lipid compound, and the use of the lipid compound in a pharmaceutical composition as well as for a method of delivering a therapeutic agent.

IONIZABLE CATIONIC COMPOUND

Resumen de: AU2024217713A1

Novel ionizable lipid compounds of Formula I-Het, Formula I and Formula II are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.

IONIZABLE CATIONIC COMPOUND

Resumen de: AU2024218499A1

Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.

LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES

Resumen de: WO2025171237A1

Compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.

COPOLYMERS AND LIPID COMPOSITIONS FOR LIPID NANOPARTICLES

Resumen de: WO2025168810A1

Lipid composition comprising: (i) one or more cationic lipids, preferably cationically ionizable lipids, (ii) one or more phospholipids, and (iii) one or more statistical copolymers comprising repeating units of the following formula (I-a) and repeating units of formula (II-a) wherein R1 represents a hydrogen atom or a group selected from a C1-3 alkyl group, a cyclopropyl group, and a C3 alkenyl group; R2 represents a group selected from a saturated C4-40 hydrocarbyl group; an unsaturated C4-40 hydrocarbyl group having one or more carbon-carbon double and/or triple bonds; a saturated C4-40 heterohydrocarbyl group containing 1 to 5 divalent groups selected from ether, thioether, sulfone, sulfoxide, keto, ester, amide, carbamate and carbonate groups, and/or 1 to 5 fluorine atoms as substituents; and an unsaturated C4-40 heterohydrocarbyl group having one or more carbon-carbon double and/or triple bonds, and containing 1 to 5 divalent groups selected from ether, keto, ester, and carbonate groups and/or 1 to 5 fluorine atoms as substituents; and x and y independently represent 0 or 1.

NANOPARTICLES FUNCTIONALISED WITH A STABILISING AGENT AND A TARGETING AGENT

Resumen de: WO2025168254A1

The present invention relates to functionalised nanoparticles. The present invention also relates to compositions comprising the functionalised nanoparticles, kits, processes for preparing nanoparticles, methods of treating cancer (including prostate cancer), imaging methods, diagnostic methods, methods for killing or attenuating the growth of a cancer cell in vitro, nanoparticles and compositions for use in the treatment of cancer or diagnosis, and a novel pepducin.

핵산-지질 입자

Resumen de: WO2024133486A1

The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in preventing and/or treating a disease, in particular for use in preventing and/or treating cancer. The present invention furthermore pertains to a method for producing a composition comprising said nucleic acid-lipids particles.

Cell-permeable nanoparticles containing albumin and cell-penetrating peptide and method for producing the same

Resumen de: KR20250122777A

기존 침투성 단백질 물질은 생체 내 분해, 흡수, 배출 등 약물동태학의 한계로 인하여 의약품 개발에 어려움이 있다. 따라서 알부민과 세포 침투성 펩타이드(Cell-Penetrating Peptide; CPP)를 이용하여 만든 세포 투과성 나노입자가 기존 세포 침투성 펩타이드의 한계를 극복하고 유용하게 쓰일 수 있음을 확인하고 본 발명을 완성하였다.

NLRP3 Anti-inflammatory composition by optogenetic stimulation comprising nanoparticle containing agent for inhibiting formation of nod-like receptor protein 3 inflammasome as effective component

Resumen de: WO2025170309A1

The present invention relates to an optogenetic anti-inflammatory composition containing, as an active ingredient, nanoparticles including an agent for inhibiting the formation of the nod-like receptor protein 3 (NLRP3) inflammasome, wherein the nanoparticles contain: a vector including a polynucleotide encoding a truncated version of cryptochrome-interacting basic-helix-loop-helix 1 (CIBN)-NLRP3 fusion protein; and a vector including a polynucleotide encoding the cryptochrome 2 (CRY2) protein or a variant thereof. The optogenetic anti-inflammatory composition has excellent anti-inflammatory activity due to non-invasive light stimulation and can thus be highly effectively used in related fields.

MATERIAL AND METHOD OF NUCLEIC ACID DELIVERY CROSSING THE BLOOD‑BRAIN BARRIER AND OTHER BLOOD-TISSUE BARRIERS

Resumen de: WO2025171161A1

Described herein are methods directed to delivering therapeutic agents across the blood-brain barrier (BBB) or other tissue barriers in subjects requiring treatment or care. The method involves obtaining a small molecule comprising a Janus Base with Amino Acid (JBAA) and mixing it in a solution with a therapeutic agent and processing the mixture with sonication to form a nanoparticle (NP) encapsulating the therapeutic agent. The NP is then administered to the subject, facilitating the crossing of the BBB or other tissue barriers to deliver the therapeutic agent directly to target cells. This approach enhances the delivery efficiency of therapeutic agents to specific sites within the body, potentially improving treatment outcomes for conditions requiring targeted delivery across biological barriers.

PHLIP ®-LNP FOR TARGETED INTRACELLULAR DELIVERY OF NUCLEIC ACID THERAPEUTICS

Resumen de: WO2025171027A1

Compositions comprising multiple pHLIP® peptides linked to a lipid nanoparticle encapsulating one or more nucleic acids (pHLIP®-LNP) and methods of preparing the pHLIP®-LNPs are described.

LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME

Resumen de: WO2025171300A1

Described are compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).

METHODS FOR PRODUCING DERMATOLOGICAL GEL COMPOSITIONS

Resumen de: WO2025171327A1

The disclosure provides a method for preparing a gel formulation comprising (a) sterilizing a first portion, wherein the first portion comprises a gelling agent, and (b) filtering a second portion to remove submicron contaminants, wherein the second portion comprises an aqueous carrier, one or more buffers, an antioxidant, an antimicrobial, a humectant, and a penetration enhancer, and following step (a) and step (b), contacting the first portion with the second portion to produce the gel formulation.

BIODEGRADABLE MAGNESIUM OR MAGNESIUM OXIDE-NANOMETAL CATALYST COMPOSITE PARTICLES FOR REACTIVE OXYGEN SPECIES CONTROL AND USES THEREOF

Resumen de: WO2025170419A1

The present invention relates to a nano-metal composite particle comprising magnesium oxide and manganese oxide, a use of the composite particle as a nanozyme utilizing the ability to scavenge reactive oxygen species, and a manufacturing method therefor.

MESOPOROUS CERIA NANOPARTICLES FOR PREVENTION, TREATMENT, OR ALLEVIATION OF OPHTHALMIC DISEASES

Resumen de: WO2025170320A1

Disclosed herein are mesoporous ceria nanoparticles for the prevention, treatment, or alleviation of ophthalmic diseases. In one aspect, having mesoporous structure with high surface area and pore size and mimicking the catalytic properties of catalase and superoxide dismutase (SOD), the mesoporous ceria nanoparticles of the present invention have excellent ability to scavenge reactive oxygen species, exhibit anti-inflammatory effects, demonstrate biocompatibility without causing acute side effects or ocular toxicity in the retina, and are recognized to provide protective effects against cellular damage and protect damaged retinal pigment epithelial (RPE) cells and photoreceptors under high oxidative stress. Therefore, the nanoparticles can be utilized for the prevention, treatment, or alleviation of macular degeneration and various oxidative stress-mediated ophthalmic diseases.

RECEPTOR- AND MAGNETIC FIELD-TARGETED DRUG CARRIER SYSTEM FOR LIVER CANCER

Resumen de: WO2025170561A1

The invention relates to a drug carrier system, which is an acyaloglycoprotein receptor and magnetically targeted, arabinogalactan-functionalised and doxorubicin-loaded magnetic nanoparticle.

OPTOGENETIC ANTI-INFLAMMATORY COMPOSITION CONTAINING NANOPARTICLES INCLUDING AGENT FOR INHIBITING FORMATION OF NLRP3 INFLAMMASOME AS ACTIVE INGREDIENT

Resumen de: WO2025170309A1

The present invention relates to an optogenetic anti-inflammatory composition containing, as an active ingredient, nanoparticles including an agent for inhibiting the formation of the nod-like receptor protein 3 (NLRP3) inflammasome, wherein the nanoparticles contain: a vector including a polynucleotide encoding a truncated version of cryptochrome-interacting basic-helix-loop-helix 1 (CIBN)-NLRP3 fusion protein; and a vector including a polynucleotide encoding the cryptochrome 2 (CRY2) protein or a variant thereof. The optogenetic anti-inflammatory composition has excellent anti-inflammatory activity due to non-invasive light stimulation and can thus be highly effectively used in related fields.

ECTOSOME COMPRISING CORONA-VIRUS SPIKE PROTEIN AND USE THEREOF

Resumen de: WO2025170343A1

The present invention provides: an ectosome comprising a corona-virus spike protein, wherein the ectosome exhibits improved drug delivery efficiency to lung cancer cells without side effects, and thus exhibits excellent anticancer efficacy; and a use thereof.

STEM CELL-DERIVED NANO ANTICANCER DRUG DELIVERY SYSTEM HAVING IMPROVED TARGETING ABILITY BY USING DEXAMETHASONE

Resumen de: WO2025170342A1

The present invention provides stem cell-derived membrane vesicle-liposome fusion nanoparticles and a use thereof, the nanoparticles exhibiting tumor site targeting ability and anticancer efficacy superior to those of a conventional drug delivery system having targeting ability.

METHOD FOR CONCENTRATING LIPID NANOPARTICLE-CONTAINING LIQUID, SOLVENT EXCHANGE METHOD FOR LIPID NANOPARTICLE-CONTAINING LIQUID, AND METHOD FOR PRODUCING LIPID NANOPARTICLE CONCENTRATED LIQUID

Resumen de: WO2025169954A1

Provided is a method for concentrating a lipid nanoparticle-containing liquid, the method comprising a step for filtering a lipid nanoparticle-containing liquid with a polyacrylonitrile-based ultrafiltration membrane.

PLANT PROTEIN-GREEN TEA POLYPHENOL CONJUGATES AS EMULSIFIERS

Resumen de: WO2025169152A1

Disclosed is a process for the assembly of protein-polyphenol conjugate stabilized nanoemulsions (PPCSNEs) by a process that comprises: (a) combining (i) a first surfactant comprised of a pre-synthesized composite species made up of a biocompatible protein and polyphenolic species, (ii) a therapeutic amount of one or more psychedelic APIs, (iii) a triglyceride oil, and optionally (iv) a co- surfactant in a container, (b) high-shear mixing said ingredients in a container to form a coarse-emulsion product, and (c) subjecting the coarse-emulsion through a microfluidic device to produce a protein-polyphenol conjugate nanoemulsion containing a psychedelic agent.

PEPTOID COMPOUND AND PEPTOID-LIPID CONJUGATE, AND USE THEREOF

Resumen de: WO2025168076A1

Disclosed herein are a peptoid compound and a peptoid conjugate such as a peptoid-lipid conjugate, and preparation methods therefor and the use thereof in a small molecule drug and nucleic acid delivery. Further disclosed herein are a lipid particle containing the peptoid-lipid conjugate, such as a liposome and a lipid nanoparticle, and a small molecule drug and/or a nucleic acid delivery composition containing the peptoid-lipid conjugate or the lipid particle. The peptoid-lipid conjugate, lipid particle, and small molecule drug and/or nucleic acid delivery composition that can be used for the small molecule drug and nucleic acid delivery of the present invention enable highly efficient compounding, protection, intracellular and targeted delivery and release of the small molecule drug and biomolecules, such as nucleic acids, in tissues and organs both in vitro and in vivo.

NOVEL LIPID COMPOUND AND COMPOSITION, AND NUCLEIC ACID LIPID NANOPARTICLE FORMULATION, AND SCREENING METHOD THEREFOR AND USE THEREOF

Resumen de: WO2025166993A1

A cationic lipid compound, a composition comprising the cationic lipid compound, and a use. A compound is as represented by general formula (I). Also provided are a cationic lipid compound comprising the compound, or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof. The present application also relates to an immune cell-targeted lipid nanoparticle, and a screening method therefor and a use thereof. Specifically disclosed is a use of the compound of formula (I), or the pharmaceutically acceptable salt, prodrug, or stereoisomer thereof in targeting immune cells, and also disclosed are a method for in vitro screening of lipid nanoparticles and a method for screening lipid nanoparticles suitable for delivering mRNA to various immune cells in vivo.

POLYETHYLENE GLYCOL LIPID MOLECULE CONTAINING TOCOPHEROL STRUCTURE, LIPID NANOPARTICLE CONTAINING SAME, AND USE THEREOF

Resumen de: WO2025166967A1

The present invention relates to a polyethylene glycol lipid molecule containing a tocopherol structure, a lipid nanoparticle containing same, and a use thereof. Specifically, provided are a polyethylene glycol lipid molecule containing a tocopherol and its derivative structure as shown in formula (1), a lipid nanoparticle containing same, and a preparation method therefor and a use thereof. Compared with polyethylene glycol lipid molecules conventionally used in the art, lipid nanoparticles prepared from the polyethylene glycol lipid molecule shown in formula (1) can significantly improve the delivery efficiency and expression of nucleic acids.

KIDNEY-TARGETED MRNA-LNP DELIVERY TECHNOLOGY AND DISEASE THERAPY METHOD

Resumen de: WO2025166988A1

Disclosed is a method for treating nephropathy, which comprises targeted delivery of a nucleic acid composition by means of topical administration. Renal tubular cells are transfected with neutral LNPs by means of ureteral retrograde administration, or renal glomerular cells are transfected with positive and neutral LNPs by means of abdominal aorta administration, thereby better targeting renal lesion cells. The mRNA-LNP technology can be applied to the targeted delivery of a kidney-specific cell population by means of the selection of a drug delivery way, thereby achieving therapy for kidney genetic diseases.

SUPRAMOLECULAR NANOCOMPOSITE

Resumen de: WO2025166810A1

Disclosed is a supramolecular nanocomposite, comprising an active ingredient, a carrier, and a penetration enhancer, wherein the penetration enhancer is composed of an anionic glycolipid and a glycoside derivative. The supramolecular nanocomposite intermediate is prepared into a supramolecular nanocomposite (ophthalmic) preparation by adding an osmotic pressure regulator, a gel carrier, an in-situ gel carrier, or a gel initiator, a pH regulator, a thickener, a bacteriostatic agent, water for injection, and the like. Compared with the prior art, the supramolecular nanocomposite can achieve a higher drug loading capacity, stronger penetrability, high affinity, long-lasting efficacy, and low irritation, such that the medication safety and efficacy are improved for patients.

NANOSTRUCTURE, NANOCOMPOSITE, AND IMPLEMENTATIONS THEREOF

Nº publicación: US2025256972A1 14/08/2025

Solicitante:

THERANAUTILUS PVT LTD [IN]
Theranautilus Pvt. Ltd

Resumen de: US2025256972A1

The present disclosure relates to a nanostructure containing: 50 to 80% (w/w) of a magnetic material; and 20 to 50% (w/w) of calcium silicate. The present disclosure further relates to a nanocomposite containing the nanostructure as disclosed herein with an additive. The present disclosure also provides a gel containing the nanostructure or the nanocomposite and additives, and methods thereof.